Related Experiment Video
Updated: Jun 21, 2025
Generation and Grafting of Tissue-engineered Vessels in a Mouse Model
Published on: March 18, 2015
Development of a novel 3D perfusable vascular graft model to elucidate the mechanisms for congenital heart disorders
Sunita Brimmer1,2,3, Pengfei Ji1,2,3, Jeffrey S Heinle2,3,4,5
1Laboratory for Regenerative Tissue Repair, Texas Children's Hospital, Houston, Texas, USA.
Insights
Pediatric heart transplant rejection, a major concern, may stem from early ischemia reperfusion injury. Identifying molecular markers could lead to therapies that improve transplanted heart longevity.
Area of Science:
- Cardiovascular Surgery
- Immunology
- Transplantation Biology
Background:
- Pediatric heart transplantation faces challenges from donor organ scarcity and graft rejection.
- Graft rejection leads to Cardiac Allograft Vasculopathy (CAV), but early mechanisms remain unclear.
Purpose of the Study:
- To identify early indicators of pediatric graft rejection.
- To investigate the role of ischemia reperfusion injury in CAV development.
- To develop strategies to enhance transplanted heart longevity.
Main Methods:
- Development of a perfusable vascular graft model.
- Populating the graft model with endothelial cells.
- Utilizing the model to study early ischemia reperfusion injury events.
Main Results:
- Demonstrated the feasibility of the vascular graft model for studying ischemia reperfusion injury.
- Established a platform for identifying molecular markers of early injury.
Conclusions:
- Early ischemia reperfusion injury is hypothesized as a key factor in pediatric heart transplant rejection and CAV.
- Identifying molecular markers of this injury may enable new therapeutic strategies.
- This research aims to improve long-term outcomes for pediatric heart transplant recipients.
Abstract:
Pediatric heart transplantation is hampered by a chronic shortage of donor organs. This problem is further confounded by graft rejection. Identification of earlier indicators of pediatric graft rejection and development of subsequent strategies to counteract these effects will increase the longevity of transplanted pediatric hearts. Heart transplant reject is due to a complex series of events, resulting in CAV, which is thought to be mediated through a host immune response. However, the earlier events leading to CAV are not very well known. We hypothesize that early events related to ischemia reperfusion injury during pediatric heart transplantation are responsible for CAV and subsequent graft rejection. Identification of the molecular markers of ischemia reperfusion injury and development of subsequent therapies to block these pathways can potentially lead to a therapeutic strategy to reduce CAV and increase the longevity of the transplanted heart. To accomplish this goal, we have developed a perfusable vascular graft model populated with endothelial cells and demonstrated the feasibility of this model to understand the early events of ischemia reperfusion injury.
